Country
Clinical Trials in Ghana
Studies with at least one site in Ghana. Open a trial for its sites in Ghana, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 51Trauma, Appendectomy
Hospital Based Continuous Patient Monitoring System
In Ghana, and many other low and middle income countries in Africa, manual vital signs monitoring is the prevalent mode of vital signs monitoring because continuous bedside monitors are non-functional.
- Conditions
- Trauma, Appendectomy, Pediatric ALL, Vital Signs Monitoring
- Trial name
- NCT06739447
- Testing
- Consumer Wearable Device Vital Sign Measurement
- Where
- Ghana
- Volunteers
- 250 people
- Sponsor
- University of Alabama at Birmingham
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Unaccompanied Migration
Testing the Impact of Family-Based Intervention to Improve Developmental and Health Outcomes for Female Adolescents
This study seeks to address the urgent need for theoretically and empirically informed interventions that would address the increasing numbers of unaccompanied minors migrating from rural to urban centers in developing countries…
- Trial name
- NCT07278934
- Testing
- ANZANSI Family Program
- Where
- Ghana
- Volunteers
- 1,920 people, healthy volunteers welcome
- Sponsor
- New York University
Child Malnutrition
7-Day vs 1-Day Packaging for Small Quantity Lipid-Based Nutrient Supplements in Ghana (SQLNS:7D-1D Comparison)
This cluster-randomized crossover trial evaluates whether the packaging format of small-quantity lipid-based nutrient supplements (SQ-LNS) affects caregiver adherence and acceptability when SQ-LNS are delivered through routine…
- Trial name
- SQLNS:7Dv1D (NCT07129109)
- Testing
- small-quantity lipid-based nutrient supplements (SQ-LNS)
- Where
- Ghana
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.
The goal of this clinical trial is to learn if Gemcitabine, a chemotherapy drug that is usually used to treat breast cancer after other treatments have failed, is better at treating triple negative breast cancer in women of…
- Trial name
- NCT07528768
- Testing
- Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly
- Where
- 3 sites in Barbados, Ghana and 1 more
- Volunteers
- 750 people
- Sponsor
- The University of The West Indies
Sickle Cell Disease, Thalassemia
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.
- Trial name
- FLORAL (NCT06609226)
- Testing
- Etavopivat A, Etavopivat B, Etavopivat C
- Where
- 107 sites in United States, Canada and 15 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Sickle Cell Disease
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle…
- Trial name
- Hibiscus 2 (NCT06612268)
- Testing
- Etavopivat
- Where
- 175 sites in United States, Australia and 19 more
- Volunteers
- 510 people
- Sponsor
- Novo Nordisk A/S
Heart Failure
30 Days and 90 Days Heart Failure Re-Admission at Komfo Anokye Teaching Hospital
In Ghana, about 88.3 per cent of cardiac admissions are due to Heart failure, making it the leading cause of admission due to heart conditions.
- Trial name
- HeFRA (NCT07100561)
- Testing
- Extensive post discharge counselling and phone-based follow up
- Where
- Ghana
- Volunteers
- 220 people
- Sponsor
- Komfo Anokye Teaching Hospital
Sepsis
Development of Context-Adapted Quality Indicators for Early Sepsis Care in Sub-Saharan Africa - A Modified Delphi Consensus Procedure
The research project is an anonymous, prospective, non-interventional consensus study in the form of a modified Delphi method, consisting of three online surveys and structured feedback meetings without recording.
- Trial name
- NCT07711535
- Where
- Ghana
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Completed, with results posted
All 37Monkey Pox, Monkeypox
Mpox Paediatric and Adolescent Clinical Study
The goal of this multicentre, observational study on mpox in infants, children and adolescents is to increase knowledge about mpox infection and its associated disease in infants, children and adolescents.
- Trial name
- NCT05947786
- Where
- 6 sites in United States, Democratic Republic of the Congo and 4 more
- Volunteers
- 1,108 people
- Sponsor
- PENTA Foundation
SARS-CoV-2 Infection
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
- Trial name
- SCORPIO-HR (NCT05305547)
- Testing
- S-217622
- Where
- 196 sites in United States, Argentina and 15 more
- Volunteers
- 2,093 people
- Sponsor
- Shionogi
Independent Child Migration
Intervention to Improve Developmental and Health Outcomes for Female Adolescents
The primary goal of this pilot study (R21) is to address the urgent need for theoretically and empirically informed interventions that prevent poor female youth's rural-to-urban migration for child labor in low and middle-income…
- Trial name
- NCT04231669
- Testing
- Anzansi Family Program
- Where
- Ghana
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Blood Pressure, Stroke
Phone-based Intervention Under Nurse Guidance After Stroke 2
The overall objective of Phone-based Intervention under Nurse Guidance after Stroke II (PINGS-2) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a theoretical-model-based, mHealth technology-centered…
- Conditions
- Blood Pressure, Stroke, Cardiovascular Diseases
- Trial name
- NCT04404166
- Testing
- PINGS 2, Standard of Care
- Where
- 10 sites in Ghana
- Volunteers
- 500 people
- Sponsor
- Northern California Institute of Research and Education
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health